Interestingly, greater efficacy in restoring lung function and decreasing fibrosis markers, such as collagen deposition or other ECM proteins, was demonstrated in the mouse model of IPF following the synergistic use of SAMiRNAs specific for AREG and connective tissue growth factor (CTGF) compared to the use of SAMiRNAs for AREG or CTGF alone. The gene discussed is CCN2; the disease is idiopathic pulmonary fibrosis.